<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">30869149</PMID><DateCompleted><Year>2020</Year><Month>02</Month><Day>21</Day></DateCompleted><DateRevised><Year>2023</Year><Month>09</Month><Day>16</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1537-6613</ISSN><JournalIssue CitedMedium="Internet"><Volume>220</Volume><Issue>3</Issue><PubDate><Year>2019</Year><Month>Jul</Month><Day>02</Day></PubDate></JournalIssue><Title>The Journal of infectious diseases</Title><ISOAbbreviation>J Infect Dis</ISOAbbreviation></Journal><ArticleTitle>Rapid Disappearance of Poliovirus Type 2 (PV2) Immunity in Young Children Following Withdrawal of Oral PV2-Containing Vaccine in Vietnam.</ArticleTitle><Pagination><StartPage>386</StartPage><EndPage>391</EndPage><MedlinePgn>386-391</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1093/infdis/jiz124</ELocationID><Abstract><AbstractText Label="BACKGROUND">Due to global shortage of inactivated poliovirus vaccine and withdrawal of oral vaccine containing poliovirus type 2 (PV2), a PV2-containing vaccine was not used in Vietnam May 2016 to October 2018. We assessed the population immunity gap to PV2.</AbstractText><AbstractText Label="METHODS">A cross-sectional survey in children aged 1-18 months was carried out in January 2018. One blood sample per child was analyzed for presence of poliovirus neutralizing antibodies. In children with detectable anti-PV2 antibodies, a second sample was analyzed 4 months later to distinguish between passive (maternally derived) and active (induced by secondary transmission or vaccination) immunity.</AbstractText><AbstractText Label="RESULTS">Sera were obtained from 1106/1110 children. Seroprevalence of PV2 antibodies was 87/368 (23.6%) at age 1-7 months, 27/471 (5.7%) at 8-15 months, and 19/267 (7.1%) at 16-18 months. Seroprevalence declined with age in the 1-7 months group; in the 8-18 months group there was no significant change with age. Four months later, 11/87 (14%), 9/27 (32%), and 12/19 (37%) remained seropositive in 1-7, 8-15, and 16-18 months age groups, respectively.</AbstractText><AbstractText Label="CONCLUSIONS">We found declining immunity to PV2, suggesting Vietnam is at risk for an outbreak of type 2 vaccine-derived poliovirus following virus importation or new emergence.</AbstractText><CopyrightInformation>&#xa9; The Author(s) 2019. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Huyen</LastName><ForeName>Dang Thi Thanh</ForeName><Initials>DTT</Initials><AffiliationInfo><Affiliation>National Institute of Hygiene and Epidemiology, Hanoi, Vietnam.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mach</LastName><ForeName>Ondrej</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Polio Eradication Department, World Health Organization, Geneva, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thanh Trung</LastName><ForeName>Nguyen</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>National Institute of Hygiene and Epidemiology, Hanoi, Vietnam.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thai</LastName><ForeName>Pham Quang</ForeName><Initials>PQ</Initials><AffiliationInfo><Affiliation>National Institute of Hygiene and Epidemiology, Hanoi, Vietnam.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thang</LastName><ForeName>Ho Vinh</ForeName><Initials>HV</Initials><AffiliationInfo><Affiliation>Pasteur Institute, Ho Chi Minh City, Vietnam.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weldon</LastName><ForeName>William C</ForeName><Initials>WC</Initials><AffiliationInfo><Affiliation>Division of Viral Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oberste</LastName><ForeName>M Steven</ForeName><Initials>MS</Initials><AffiliationInfo><Affiliation>Division of Viral Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jeyaseelan</LastName><ForeName>Visalakshi</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Polio Eradication Department, World Health Organization, Geneva, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sutter</LastName><ForeName>Roland W</ForeName><Initials>RW</Initials><AffiliationInfo><Affiliation>Polio Eradication Department, World Health Organization, Geneva, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Anh</LastName><ForeName>Dang Duc</ForeName><Initials>DD</Initials><AffiliationInfo><Affiliation>National Institute of Hygiene and Epidemiology, Hanoi, Vietnam.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>001</GrantID><Acronym>WHO_</Acronym><Agency>World Health Organization</Agency><Country>International</Country></Grant><Grant><GrantID>CC999999</GrantID><Acronym>ImCDC</Acronym><Agency>Intramural CDC HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Infect Dis</MedlineTA><NlmUniqueID>0413675</NlmUniqueID><ISSNLinking>0022-1899</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D057134">Antibodies, Neutralizing</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011054">Poliovirus Vaccine, Inactivated</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011055">Poliovirus Vaccine, Oral</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D057134" MajorTopicYN="N">Antibodies, Neutralizing</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004196" MajorTopicYN="N">Disease Outbreaks</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007223" MajorTopicYN="N">Infant</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011051" MajorTopicYN="N">Poliomyelitis</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017955" MajorTopicYN="N">Poliovirus</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011054" MajorTopicYN="N">Poliovirus Vaccine, Inactivated</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011055" MajorTopicYN="N">Poliovirus Vaccine, Oral</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016036" MajorTopicYN="N">Seroepidemiologic Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014611" MajorTopicYN="N">Vaccination</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014744" MajorTopicYN="N" Type="Geographic">Vietnam</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Vietnam</Keyword><Keyword MajorTopicYN="N">eradication</Keyword><Keyword MajorTopicYN="N">poliomyelitis</Keyword><Keyword MajorTopicYN="N">vaccination</Keyword></KeywordList><CoiStatement><b><i>Potential conflicts of interest.</i></b> All authors: No reported conflicts of interest. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>2</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>3</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>3</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>2</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>3</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>5</Month><Day>5</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">30869149</ArticleId><ArticleId IdType="mid">NIHMS1798458</ArticleId><ArticleId IdType="pmc">PMC9069936</ArticleId><ArticleId IdType="doi">10.1093/infdis/jiz124</ArticleId><ArticleId IdType="pii">5380634</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>World Health Organization. Wild poliovirus list. http://www.polioeradication.org/Dataandmonitoring/Poliothisweek/Wildpolioviruslist.aspx. Accessed 27 August 2018.</Citation></Reference><Reference><Citation>Sutter RW, Platt L, Mach O, Jafari H, Aylward RB. The new polio eradication end game: rationale and supporting evidence. J Infect Dis 2014; 210(Suppl 1):S434&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">25316865</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization. Polio eradication and endgame strategic plan 2013&#x2013;2018. http://polioeradication.org/wp-content/uploads/2016/07/PEESP_EN_A4.pdf. Accessed 18 March 2019.</Citation></Reference><Reference><Citation>Hampton LM, Farrell M, Ramirez-Gonzalez A, et al. Cessation of trivalent oral poliovirus vaccine and introduction of inactivated poliovirus vaccine - worldwide, 2016. MMWR Morb Mortal Wkly Rep 2016; 65:934&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">27606675</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization. Meeting of the Strategic Advisory Group of Experts on immunization, November 2013 - conclusions and recommendations. Wkly Epidemiol Rec 2014; 89:1&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pubmed">24466571</ArticleId></ArticleIdList></Reference><Reference><Citation>Strategic Advisory Group of Experts (SAGE). SAGE discussion and statement in relation with the IPV supply situation. http://www.who.int/immunization/sage/meetings/2016/april/SAGE_statement_IPV_situation.pdf. Accessed 23 June 2016.</Citation></Reference><Reference><Citation>Ministry of Health Viet Nam. National expanded program on immunization comprehensive multi-year plan cMYP for extended program on immunization 2016&#x2013;2020. http://www.nationalplanningcycles.org/sites/default/files/planning_cycle_repository/viet_nam/cmyp_vietnam_2016-2020.pdf. Accessed 28 September 2018.</Citation></Reference><Reference><Citation>Centers for Disease Control and Prevention. Apparent global interruption of wild poliovirus type 2 transmission. MMWR Morb Mortal Wkly Rep 2001; 50:222&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">11300627</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang QS, Greening G, Baker MG, et al. Persistence of oral polio vaccine virus after its removal from the immunisation schedule in New Zealand. Lancet 2005; 366:394&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">16054940</ArticleId></ArticleIdList></Reference><Reference><Citation>M&#xe1;s Lago P, C&#xe1;ceres VM, Galindo MA, et al. Persistence of vaccine-derived poliovirus following a mass vaccination campaign in Cuba: implications for stopping polio vaccination after global eradication. Int J Epidemiol 2001; 30:1029&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pubmed">11689516</ArticleId></ArticleIdList></Reference><Reference><Citation>M&#xe1;s Lago P, Gary HE Jr, P&#xe9;rez LS, et al. Poliovirus detection in wastewater and stools following an immunization campaign in Havana, Cuba. Int J Epidemiol 2003; 32:772&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">14559748</ArticleId></ArticleIdList></Reference><Reference><Citation>Nathanson N, Kew OM. From emergence to eradication: the epidemiology of poliomyelitis deconstructed. Am J Epidemiol 2010; 172:1213&#x2013;29.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2991634</ArticleId><ArticleId IdType="pubmed">20978089</ArticleId></ArticleIdList></Reference><Reference><Citation>Weldon WC, Oberste MS, Pallansch MA. Standardized methods for detection of poliovirus antibodies. Methods Mol Biol 2016; 1387:145&#x2013;76.</Citation><ArticleIdList><ArticleId IdType="pubmed">26983734</ArticleId></ArticleIdList></Reference><Reference><Citation>Wikipedia. Bootstrapping (statistics). https://en.wikipedia.org/wiki/Bootstrapping_(statistics). Accessed 18 March 2019.</Citation></Reference><Reference><Citation>Gelfand HM, Fox JP, Leblanc DR, Elveback L. Studies on the development of natural immunity to poliomyelitis in Louisiana. V. Passive transfer of polioantibody from mother to fetus, and natural decline and disappearance of antibody in the infant. J Immunol 1960; 85:46&#x2013;55.</Citation><ArticleIdList><ArticleId IdType="pubmed">13827179</ArticleId></ArticleIdList></Reference><Reference><Citation>Patriarca PA, Wright PF, John TJ. Factors affecting the immunogenicity of oral poliovirus vaccine in developing countries: review. Rev Infect Dis 1991; 13:926&#x2013;39.</Citation><ArticleIdList><ArticleId IdType="pubmed">1660184</ArticleId></ArticleIdList></Reference><Reference><Citation>Ji B, Hu H, Zhao Y, Mu X, Liu K, Li C. Effects of deep tillage and straw returning on soil microorganism and enzyme activities. ScientificWorldJournal 2014; 2014:451493.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3984811</ArticleId><ArticleId IdType="pubmed">24982955</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>